WallStreetZenWallStreetZen

NASDAQ: RAPP
Rapport Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RAPP

Based on 4 analysts offering 12 month price targets for Rapport Therapeutics Inc

Min Forecast
$46.00+12.25%
Avg Forecast
$54.75+33.6%
Max Forecast
$65.00+58.61%

Should I buy or sell RAPP stock?

Based on 4 analysts offering ratings for Rapport Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RAPP's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates RAPP as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their RAPP stock forecasts and price targets.

RAPP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-07-16
lockedlocked$00.00+00.00%2026-06-24
lockedlocked$00.00+00.00%2026-05-19Find Out Why
lockedlocked$00.00+00.00%2026-03-11

1 of 1

Forecast return on equity

Is RAPP forecast to generate an efficient return?

Company
-49.47%
Industry
87.23%
Market
180.82%
RAPP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RAPP forecast to generate an efficient return on assets?

Company
-46.88%
Industry
26.37%
RAPP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RAPP earnings per share forecast

What is RAPP's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$3.53
Avg 2 year Forecast
-$4.45
Avg 3 year Forecast
-$4.86

RAPP revenue forecast

What is RAPP's revenue in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$20.4M+2%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%

RAPP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RAPP$40.98$54.75+33.60%Strong Buy
ADMA$8.46$17.50+106.86%Strong Buy
VRDN$18.92$32.50+71.78%Strong Buy
ZBIO$31.44$40.50+28.82%Strong Buy
PVLA$139.04$239.00+71.89%Strong Buy
View Top Biotech Stocks

Rapport Therapeutics Stock Forecast FAQ

Is Rapport Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: RAPP) stock is to Strong Buy RAPP stock.

Out of 4 analysts, 3 (75%) are recommending RAPP as a Strong Buy, 1 (25%) are recommending RAPP as a Buy, 0 (0%) are recommending RAPP as a Hold, 0 (0%) are recommending RAPP as a Sell, and 0 (0%) are recommending RAPP as a Strong Sell.

If you're new to stock investing, here's how to buy Rapport Therapeutics stock.

What is RAPP's earnings growth forecast for 2026-2028?

(NASDAQ: RAPP) Rapport Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.91%.

Rapport Therapeutics's earnings in 2026 is -$107,277,000.On average, 14 Wall Street analysts forecast RAPP's earnings for 2026 to be -$168,647,317, with the lowest RAPP earnings forecast at -$178,107,484, and the highest RAPP earnings forecast at -$150,654,826. On average, 14 Wall Street analysts forecast RAPP's earnings for 2027 to be -$212,738,963, with the lowest RAPP earnings forecast at -$276,066,600, and the highest RAPP earnings forecast at -$164,213,761.

In 2028, RAPP is forecast to generate -$232,371,917 in earnings, with the lowest earnings forecast at -$290,127,717 and the highest earnings forecast at -$197,357,823.

What is RAPP's revenue growth forecast for 2026-2028?

(NASDAQ: RAPP) Rapport Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.72%.

Rapport Therapeutics's revenue in 2026 is $20,000,000.On average, 15 Wall Street analysts forecast RAPP's revenue for 2026 to be $975,669,352, with the lowest RAPP revenue forecast at $937,407,808, and the highest RAPP revenue forecast at $1,004,365,509. On average, 15 Wall Street analysts forecast RAPP's revenue for 2027 to be $0, with the lowest RAPP revenue forecast at $0, and the highest RAPP revenue forecast at $0.

In 2028, RAPP is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is RAPP's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: RAPP) forecast ROA is -46.88%, which is lower than the forecast US Biotechnology industry average of 26.37%.

What is RAPP's Price Target?

According to 4 Wall Street analysts that have issued a 1 year RAPP price target, the average RAPP price target is $54.75, with the highest RAPP stock price forecast at $65.00 and the lowest RAPP stock price forecast at $46.00.

On average, Wall Street analysts predict that Rapport Therapeutics's share price could reach $54.75 by Jul 16, 2027. The average Rapport Therapeutics stock price prediction forecasts a potential upside of 33.6% from the current RAPP share price of $40.98.

What is RAPP's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: RAPP) Rapport Therapeutics's current Earnings Per Share (EPS) is -$2.59. On average, analysts forecast that RAPP's EPS will be -$3.53 for 2026, with the lowest EPS forecast at -$3.72, and the highest EPS forecast at -$3.15. On average, analysts forecast that RAPP's EPS will be -$4.45 for 2027, with the lowest EPS forecast at -$5.77, and the highest EPS forecast at -$3.43. In 2028, RAPP's EPS is forecast to hit -$4.86 (min: -$6.07, max: -$4.13).

What is RAPP's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: RAPP) forecast ROE is -49.47%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.